Novo Nordisk successfully prices EUR 1.3 billion notes under its newly established Euro Medium Term Note programme

NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.

Bagsværd, Denmark, 27 May 2021 - Novo Nordisk today announced the successful launch and pricing of the first Eurobond issuance under its newly established EUR 5 billion Euro Medium Term Note (EMTN) programme in two tranches with an aggregate principal amount of EUR 1.3 billion.

The first tranche maturing on 4 June 2024 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0%. The second tranche maturing on 4 June 2028 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0.125%. Net proceeds of the issuances will be used by Novo Nordisk for general corporate purposes, including refinancing of the bridge loan facility established in connection with Novo Nordisk’s acquisition of Emisphere Technologies Inc. in 2020. Both bonds will be issued on 4 June 2021 and will be listed on Euronext Dublin.

Standard & Poor’s and Moody’s rated the notes at AA- and A1 in line with Novo Nordisk’s company ratings of AA- and A1 with stable outlook.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
  
 Further information

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in or into any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any investment decision made in connection with the Notes MUST be based solely on the information contained in the base prospectus in relation to the Programme published on 20 May 2021 (the "Prospectus") and the Final Terms to be published in in connection with the Notes (the “Final Terms”).

Please note that the information contained in the Prospectus and the Final Terms is addressed to and/or targeted at persons who are residents of particular countries (as specified in the Prospectus and the Final Terms) only and is not intended for use and should not be relied upon by any person outside those countries and/or to whom the offer contained in the Prospectus and the Final Terms is not addressed. Prior to relying on the information contained in the Prospectus and the Final Terms you must ascertain from the Prospectus and the Final Terms whether or not you are part of the intended addressees of the information contained therein. No action has been taken that would, or is intended to, permit a public offer of the Notes in any country or jurisdiction where any such action for that purpose is required.

THIS ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S) UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). ANY PERSON WHO RECEIVES THIS ANNOUNCEMENT CONTRARY TO THE FOREGOING SHOULD NOT ACT OR RELY ON THIS ANNOUNCEMENT OR ANY OF ITS CONTENTS IN RELATION TO THE SECURITIES. THE SECURITIES DESCRIBED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

Attachment

• PR20210527_Bond issuance_EMTN_programme